Cardiovascular risk during hormonal treatment in patients with prostate cancer

References

• HeidenreichAAusGBollaMEAU guidelines on prostate cancerEur Urol200853688017920184
   PubMed Web of Science ®Google Scholar
• AlibhaiSMGogovSAllibhaiZLong-term side effects of ADT in men with non-metastatic prostate cancer: A systematic literature reviewCrit Rev Oncol Hematol20066020121516860998
   PubMed Web of Science ®Google Scholar
• SmithJCBennettSEvansLMThe effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancerJ Clin Endocrinol Metab2001864261426711549659
   PubMed Web of Science ®Google Scholar
• SmithMRFinkelsteinJSMcGovernFJChanges in body composition during ADT for prostate cancerJ Clin Endocrinol Metab20028759960311836291
   PubMed Web of Science ®Google Scholar
• BerrutiADogliottiLTerroneCChanges in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given ADTJ Urol20021672361236711992038
   PubMed Web of Science ®Google Scholar
• SmithMRChanges in fat and lean body mass during androgen-deprivation therapy for prostate cancerUrology20046374274515072892
   PubMed Web of Science ®Google Scholar
• SmithMRLeeHNathanDMInsulin sensitivity during combined androgen blockade for prostate cancerJ Clin Endocrinol Metab2006911305130816434464
   PubMed Web of Science ®Google Scholar
• DockeryFBulpittCJAgarwalSDonaldsonMRajkumarCTestosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemiaClin Sci (Lond)200310419520112546642
   PubMed Web of Science ®Google Scholar
• GalvaoDASpryNATaaffeDRChanges in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancerBJU Int2008102444718336606
   PubMed Web of Science ®Google Scholar
• SmithMRLeeHMcGovernFMetabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: Differences from the classic metabolic syndromeCancer20081122188219418348297
   PubMed Web of Science ®Google Scholar
• Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in AdultsJAMA20012852486249711368702
   PubMed Web of Science ®Google Scholar
• Braga-BasariaMDobsASMullerDCMetabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapyJ Clin Oncol2006243979398316921050
   PubMed Web of Science ®Google Scholar
• GarnickMBPrattCMCampionMShipleyJThe effect of hormonal therapy for prostate cancer on the electrocardiographic QT interval: Phase 3 results following treatment with leuprolide and goserelin, alone or with bicalutamide, and the gonadotropin-releasing hormone antagonist abarelixJ Clin Oncol200422 Abstr 4578.
   Web of Science ®Google Scholar
• KeatingNLO’MalleyAJFreedlandSJSmithMRDiabetes and cardiovascular disease during ADT: Observational study of veterans with prostate cancerJ Natl Cancer Inst2009102394619996060
   PubMedGoogle Scholar
• KeatingNLO’MalleyAJSmithMRDiabetes and cardiovascular disease during ADT for prostate cancerJ Clin Oncol2006244448445616983113
   PubMed Web of Science ®Google Scholar
• SaigalCSGoreJLKrupskiTLHanleyJSchonlauMLitwinMSAndrogen deprivation therapy increases cardiovascular morbidity in men with prostate cancerCancer20071101493150017657815
   PubMed Web of Science ®Google Scholar
• AlibhaiSMDuong-HuaMSutradharRImpact of ADT on cardiovascular disease and diabetesJ Clin Oncol2009273452345819506162
   PubMed Web of Science ®Google Scholar
• TsaiHKD’AmicoAVSadetskyNChenMHCarrollPRAndrogen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortalityJ Natl Cancer Inst2007991516152417925537
   PubMed Web of Science ®Google Scholar
• NandaAChenMHBraccioforteMHMoranBJD’AmicoAVHormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarctionJAMA200930286687319706860
   PubMed Web of Science ®Google Scholar
• D’AmicoAVDenhamJWCrookJInfluence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctionsJ Clin Oncol2007252420242517557956
   PubMed Web of Science ®Google Scholar
• StuderUEWhelanPAlbrechtWImmediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891J Clin Oncol2006241868187616622261
   PubMed Web of Science ®Google Scholar
• RoachM3rdBaeKSpeightJShort-term neoadjuvant ADT and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610J Clin Oncol20082658559118172188
   PubMed Web of Science ®Google Scholar
• EfstathiouJABaeKShipleyWUCardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: Analysis of RTOG 92-02Eur Urol20085481682318243498
   PubMed Web of Science ®Google Scholar
• EfstathiouJABaeKShipleyWUCardiovascular mortality after ADT for locally advanced prostate cancer: RTOG 85-31J Clin Oncol200927929919047297
   PubMed Web of Science ®Google Scholar
• BollaMde ReijkeTMvan TienhovenGDuration of androgen suppression in the treatment of prostate cancerN Engl J Med20093602516252719516032
   PubMed Web of Science ®Google Scholar
• Van HemelrijckMGarmoHHolmbergLAbsolute and relative risk of cardiovascular disease in men with prostate cancer: Results from the population-based PCBaSe SwedenJ Clin Oncol2010283448345620567006
   PubMed Web of Science ®Google Scholar
• LevineGND’AmicoAVBergerPAndrogen-deprivation therapy in prostate cancer and cardiovascular risk: A science advisory from the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation OncologyCA Cancer J Clin20106019420120124400
   PubMed Web of Science ®Google Scholar
• ShahaniSBraga-BasariaMBasariaSAndrogen deprivation therapy in prostate cancer and metabolic risk for atherosclerosisJ Clin Endocrinol Metab2008932042204918349064
   PubMed Web of Science ®Google Scholar
• SegalRJReidRDCourneyaKSResistance exercise in men receiving ADT for prostate cancerJ Clin Oncol2003211653165912721238
   PubMed Web of Science ®Google Scholar
• GalvaoDANosakaKTaaffeDRResistance training and reduction of treatment side effects in prostate cancer patientsMed Sci Sports Exerc2006382045205217146309
   PubMed Web of Science ®Google Scholar
• GalvaoDANosakaKTaaffeDREndocrine and immune responses to resistance training in prostate cancer patientsProstate Cancer Prostatic Dis20081116016517637762
   PubMed Web of Science ®Google Scholar
• SegalRJReidRDCourneyaKSRandomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancerJ Clin Oncol20092734435119064985
   PubMed Web of Science ®Google Scholar
• AbrahamssonPAPotential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: A systematic review of the literatureEur Urol201057495919683858
   PubMed Web of Science ®Google Scholar
• D’AmicoAVRenshawAALoffredoBChenMHDuration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapyCancer20071101723172817828774
   PubMed Web of Science ®Google Scholar
• KakuHSaikaTTsushimaTTime course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancerProstate20066643944416329145
   PubMed Web of Science ®Google Scholar
• KhawKTDowsettMFolkerdEEndogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population StudyCirculation20071162694270118040028
   PubMed Web of Science ®Google Scholar
• SmithMRGoodeMZietmanALMcGovernFJLeeHFinkelsteinJSBicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: Effects on bone mineral density and body compositionJ Clin Oncol2004222546255315226323
   PubMed Web of Science ®Google Scholar